Prognostic impact of HLA‐I neoantigen‐specific CD8+ T cells in limited‐stage follicular lymphoma.

Authors :: Tobin, J. W.
Tsang, H.
Patch, A.
Keane, C.
Law, S. C.
Gunawardana, J.
Blombery, P.
Thompson, E. R.
Sabdia, M. B.
De Long, L. M.
Nath, K.
Kazakoff, S. H.
Cheah, C.
Amanuel, B.
Cochrane, T.
Butler, J.
Johnston, A.
Shanavas, M.
Li, L.
Shelton, V.
Source :: Hematological Oncology; Jun2023 Supplement 1, Vol. 41, p276-277, 2p
Publication Year :: 2023
Abstract: Durable remissions occur in ~50% of LSFL patients whereas ASFL is incurable. In keeping with recent IHC CD8 protein data (Los-de Vries, Bld Adv 2022), CD8A gene expression was raised in stage I LSFL vs. 68 ASFL patients treated with immunochemotherapy ( I p i = 0.02). Recently, we demonstrated in limited and advanced stage FL (LSFL, ASFL), that patients with longer remissions had raised clonally expanded intratumoral CD8+ T cells (Tobin, JCO 2019). [Extracted from the article]

Subjects :: FOLLICULAR lymphoma
T cells
CD8 antigen
COMBINED modality therapy

Full Text Access

Tools